AZ ROC: CR-42 320942
602.529.3332
title icon

2011 AACR Abstract: Phase I Clinical Study of Systemic TUSC2 Nanoparticle Therapy (Oncoprex®) in Stage IV Lung Cancer Patients

An abstract describing a phase I clinical trial investigating Oncoprex® (intravenous TUSC2 nanovesicles) used a single agent in recurrent, metastatic lung cancer patients. The dose escalation clinical trial was conducted at The University of Texas MD Anderson Cancer Center. The abstract was published in the Proceedings of the 2011 Annual Meeting of the American Association for Cancer Research (AACR) and was awarded a Highly Rated Paper by AACR.